Partial Thyroidectomy With Incidental Metastatic Lymph Nodes.
Journal
JAMA otolaryngology-- head & neck surgery
ISSN: 2168-619X
Titre abrégé: JAMA Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 101589542
Informations de publication
Date de publication:
16 Nov 2023
16 Nov 2023
Historique:
pmc-release:
16
11
2024
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
aheadofprint
Résumé
The need for completion thyroidectomy in patients with incidental metastatic lymph nodes after partial thyroidectomy is unclear. To investigate the outcomes of patients with incidental metastatic lymph nodes following partial thyroidectomy. A retrospective review of a prospectively maintained thyroid cancer database from 1985 to 2015 was carried out at a head and neck surgery practice at a tertiary referral cancer center. A total of 74 patients who underwent thyroid lobectomy or thyroid isthmusectomy between 1985 and 2015 and were found to have incidental metastatic lymph nodes on final pathologic analysis and were selected to be observed without immediate completion thyroidectomy were included. A separate group of additional 11 patients who underwent immediate completion thyroidectomy was also identified and reviewed. Analysis took place from February to May 2022. Recurrence-free survival outcomes of patients found to have incidental metastatic lymph nodes on final pathologic analysis following partial thyroidectomy with no immediate completion thyroidectomy. A total of 74 patients were observed, with a median (IQR) age of 39 (28-49) years; 44 (59%) were women. Sixty-four patients underwent thyroid lobectomy and 10 patients had isthmusectomy. Classic papillary thyroid carcinoma was the most common histologic type (34 [46%]). Vascular invasion and microscopic extrathyroidal extension were present in 11 patients (16%) and 22 patients (30%), respectively. Positive margins were identified in 5 patients (7.8%). Size of metastatic lymph nodes ranged between 0.07 cm and 1.2 cm. No extranodal extension was reported. A total of 52 patients (70%) were classified as intermediate risk for recurrence based on the American Thyroid Association risk stratification system. The median (IQR) follow up was 48.15 (15.4-86.1) months, during which only 1 patient had a regional recurrence. Another patient underwent delayed completion thyroidectomy for a contralateral lobe malignant abnormality. Recurrence-free survival, disease-specific survival, and overall survival were 97.4%, 100%, and 96.2%, respectively. A separate group of 11 patients who underwent immediate completion thyroidectomy were reviewed. These patients were more likely to have tall-cell papillary thyroid carcinoma (6 [55%] vs 13 [18%]), multifocality (9 [82%] vs 28 [41%]), microscopic extrathyroidal extension (8 [73%] vs 22 [30%]), and positive margins (3 [30%] vs 5 [7.8%]) compared with patients who were under observation only. Completion thyroidectomy may not be necessary in appropriately selected patients who are found to have incidental metastatic lymph nodes (N1a) after partial thyroidectomy for localized well-differentiated thyroid cancer.
Identifiants
pubmed: 37971746
pii: 2812068
doi: 10.1001/jamaoto.2023.3668
pmc: PMC10654922
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Oncol Res Treat. 2019;42(3):143-147
pubmed: 30799429
Surg Oncol. 2008 Sep;17(3):253-8
pubmed: 18504121
Ann Surg Oncol. 2021 Oct;28(11):6603-6612
pubmed: 33768393
Nat Rev Endocrinol. 2020 Jan;16(1):17-29
pubmed: 31616074
Eur J Endocrinol. 2013 Jan 17;168(2):219-25
pubmed: 23161752
Oral Oncol. 2022 Nov;134:106115
pubmed: 36108524
Thyroid. 2022 Apr;32(4):397-410
pubmed: 35078347
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
J Surg Oncol. 2017 Sep;116(3):275-280
pubmed: 28570769
Cancers (Basel). 2023 Feb 02;15(3):
pubmed: 36765899
Clin Endocrinol (Oxf). 2016 Feb;84(2):292-295
pubmed: 26041503
Surgery. 2019 Mar;165(3):652-656
pubmed: 30385127
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Ann Surg. 2003 Mar;237(3):399-407
pubmed: 12616125
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
Thyroid. 2012 Nov;22(11):1144-52
pubmed: 23083442
Future Oncol. 2016 Apr;12(7):981-94
pubmed: 26948758
Ann Surg Oncol. 2011 Mar;18(3):767-70
pubmed: 20882418
Ann Surg Oncol. 2014 Jan;21(1):277-83
pubmed: 24006096
J Laryngol Otol. 2007 Oct;121(10):986-9
pubmed: 17156579